Catalog No.
DHC90729
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BAT-4306F, BAT 4306F, BAT4306F
Clone ID
BAT 4306F
Note
For research use only. Not suitable for clinical or therapeutic use.
CXCL13 and CCL21 Induce Tertiary Lymphoid Structures and Enhance the Efficacy of Immunotherapy for Melanoma., PMID:40393449
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders., PMID:40402079
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis., PMID:40402264
Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas., PMID:40409372
Severe Hypokalemic Paralysis Following Rituximab Infusion in a Patient With Microscopic Polyangitis., PMID:40416913
Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460
The Prognostic Impact of the Tumor Immune Microenvironment in Synovial Sarcoma: An Immunohistochemical Analysis Using Digital Pathology and Conventional Interpretation., PMID:40423041
Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?, PMID:40427101
Unsupervised Clustering of Cell Populations in Germinal Centers Using Multiplexed Immunofluorescence., PMID:40427719
Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals., PMID:40431250
COVID-19 Vaccination in Patients with Hematological Malignances., PMID:40432077
Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab., PMID:40432100
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial., PMID:40434509
Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review., PMID:40438359
Ocrelizumab-Induced Hemophagocytic Lymphohistiocytosis: A Case Report., PMID:40438805
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445
Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis., PMID:40443484
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis: A Multicenter Cohort Study., PMID:40446185
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284
Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia., PMID:40456120
Pathogenesis, Diagnosis, Treatment, and Prognosis of CD20-Positive T and NK Cell Lymphoma: A Review., PMID:40460386
Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients., PMID:40464994
Oral lichen planus in a patient treated with anti-CD20 monoclonal antibodies., PMID:40465334
Targeting B Cells and Plasma Cells in Glomerular Disease., PMID:40465397
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma., PMID:40467383
[Severe late-onset neutropenia after rituximab administration]., PMID:40467890
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany., PMID:40470489
CD20×CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research., PMID:40471801
Advances in the treatment of ANCA-associated vasculitis., PMID:40473820
Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022., PMID:40473981
The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis., PMID:40474885
Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies., PMID:40475129
Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab., PMID:40480240
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective., PMID:40481170
Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study., PMID:40492601
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy., PMID:40500294
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis., PMID:40510879
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis., PMID:40512061
Native structure of the monoclonal therapeutic CD20 antibody ocrelizumab., PMID:40513927
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863
Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma., PMID:40516919
A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma., PMID:40517417
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas., PMID:40524014
Treatment Options for the Comorbidity of Multiple Sclerosis With Other Chronic Inflammatory Diseases., PMID:40526577
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma., PMID:40528731
Case Report: Unilateral relapsing primary central nervous system vasculitis-expanding the phenotype., PMID:40529356
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies., PMID:40534489
Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia., PMID:40536789
For research use only. Not for human or drug use.
